Journal
VACCINE
Volume 33, Issue 15, Pages 1873-1879Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.02.011
Keywords
Vaccination; Th1/Th2 cells; Viral infection; Adjuvant; Polio; Dose sparing
Categories
Funding
- Bill and Melinda Gates Foundation [OPP1070827]
- Bill and Melinda Gates Foundation [OPP1070827] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Background: The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority and will be essential for the complete eradication of polio. Since the aluminium hydroxide adjuvant is widely used in humans we tested this adjuvant with IPV in two models. Our objective was twofold; to examine the IPV dose sparing effect of aluminium hydroxide and how the adjuvant effect of aluminium hydroxide affected the immunity induced by IPV. Methods: Mice and rats were immunized with IPV formulated with Aluminium hydroxide and subjected to immunological analyses and serum polio virus neutralization titer determination. Results: Addition of aluminium hydroxide to IPV led to a ten times dose sparing effect compared to IPV alone, measured by virus neutralization titers in serum. Aluminium hydroxide changed the kinetics of the response against IPV leading to a faster and stronger response, which due to IPV induced immune dominance was characterized as a strong Th1-biased cellular/humoral immune response. Conclusions: The IPV-aluminium hydroxide formulation constitutes a promising vaccine capable of generating strong Th1 immunity against infection with all three serotypes. A phase I/II clinical study was recently initiated. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available